{
    "clinical_study": {
        "@rank": "77284", 
        "arm_group": [
            {
                "arm_group_label": "Group D", 
                "arm_group_type": "Experimental", 
                "description": "Group D patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) with 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg) perineurally for their femoral block.  Group D will also receive a gluteal intramuscular injection of saline of volume equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml)."
            }, 
            {
                "arm_group_label": "Group R", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Group R patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) combined with a volume of saline equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml) perineurally.  Group R will also receive a gluteal intramuscular injection of saline of volume equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml)."
            }, 
            {
                "arm_group_label": "Group M", 
                "arm_group_type": "Active Comparator", 
                "description": "Group M patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) combined with a volume of saline equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml) perineurally.  Group M will also receive a gluteal intramuscular injection of 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg)."
            }
        ], 
        "brief_summary": {
            "textblock": "If preservative-free dexamethasone 0.1 mg/kg (max dose 4 mg) is added to ropivacaine 0.5% 2\n      mg/kg (max dose 100 mg), then post-PACU opioid consumption will be reduced by 33%."
        }, 
        "brief_title": "Decadron as Adjuvant in Femoral Nerve Blocks in Knee Arthroscopy", 
        "completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Knee Arthroscopy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Children older than 10, and younger than 19 years of age undergoing unilateral\n             arthroscopic surgery of the knee\n\n          -  American Society of Anesthesiologists (ASA) Status I or II\n\n          -  Patient's parent/guardian willing and able to give consent\n\n          -  Patient willing to give assent\n\n        Exclusion Criteria:\n\n          -  Arthroscopic anterior cruciate ligament repair\n\n          -  Systemic steroid use within the last 3 months\n\n          -  Diabetes mellitus\n\n          -  Females testing positive for pregnancy\n\n          -  BMI > 98th percentile\n\n          -  Positive pregnancy test\n\n          -  Coagulopathy\n\n          -  Renal or hepatic disease\n\n          -  Pre-existing motor or sensory deficits in the lower extremities\n\n          -  Predisposition for falls based on pre-existing sensory or motor deficits of the legs\n             or inability to perform crutch training.\n\n          -  Non-English speaking\n\n          -  Systemic fungal infection\n\n          -  Immunosuppressed patients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "19 Years", 
            "minimum_age": "10 Years"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01971645", 
            "org_study_id": "IRB13-00610"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group D", 
                    "Group M"
                ], 
                "description": "Patients may receive 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg) either perineurally or intramuscularly.", 
                "intervention_name": "Dexamethasone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Group D", 
                    "Group R", 
                    "Group M"
                ], 
                "description": "Patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) perineurally.", 
                "intervention_name": "Ropivacaine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "Ropivacaine", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Dexamethasone", 
            "Ropivacaine", 
            "Knee arthroscopy", 
            "Femoral nerve blocks", 
            "Peripheral nerve blocks", 
            "Adjuvant", 
            "Pediatrics"
        ], 
        "lastchanged_date": "May 15, 2014", 
        "location": {
            "contact": {
                "email": "Giorgio.Veneziano@NationwideChildrens.org", 
                "last_name": "Giorgio Veneziano, MD", 
                "phone": "614-722-4200"
            }, 
            "contact_backup": {
                "email": "N'Diris.Barry@NationwideChildrens.org", 
                "last_name": "N'Diris Barry, BS, RN, BSN", 
                "phone": "(614) 355-3467"
            }, 
            "facility": {
                "address": {
                    "city": "Columbus", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "43205"
                }, 
                "name": "Nationwide Children's Hospital"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Dexamethasone as an Adjuvant to Ropivacaine for Femoral Nerve Blocks in Children Undergoing Knee Arthroscopy", 
        "overall_contact": {
            "email": "N'Diris.Barry@NationwideChildrens.org", 
            "last_name": "N'Diris Barry, BS, RN, BSN", 
            "phone": "(614) 355-3467"
        }, 
        "overall_contact_backup": {
            "email": "Julie.Rice@NationwideChildrens.org", 
            "last_name": "Julie Rice, RN, BSN", 
            "phone": "(614) 355-3142"
        }, 
        "overall_official": {
            "affiliation": "Nationwide Children's Hospital", 
            "last_name": "Giorgio Veneziano, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Post-PACU opioid consumption", 
            "safety_issue": "No", 
            "time_frame": "48 hours post-operatively"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01971645"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Nationwide Children's Hospital", 
            "investigator_full_name": "Giorgio Veneziano", 
            "investigator_title": "Assistant Clinical Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Nationwide Children's Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nationwide Children's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}